Philip Ballard

Residency, - School of Medicine, University of California, San Francisco
  1. Human Fetal Tissue Regulation. Impact on Pediatric and Adult Respiratory-related Research.
  2. Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant.
  3. Composition and origin of lung fluid proteome in premature infants and relationship to respiratory outcome.
  4. Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE).
  5. Optimizing antenatal corticosteroid therapy for improving outcome of premature infants.
  6. Correction: Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia.
  7. Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates.
  8. Genetic variation in CRHR1 is associated with short-term respiratory response to corticosteroids in preterm infants at risk for bronchopulmonary dysplasia.
  9. Exome sequencing identifies gene variants and networks associated with extreme respiratory outcomes following preterm birth.
  10. Ancestry and genetic associations with bronchopulmonary dysplasia in preterm infants.
  11. Surfactant status and respiratory outcome in premature infants receiving late surfactant treatment.
  12. Reply.
  13. Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial.
  14. Race Effects of Inhaled Nitric Oxide in Preterm Infants: An Individual Participant Data Meta-Analysis.
  15. Commentary on the identity of fibroblast pneumocyte factor: rat vs. human.
  16. The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age.
  17. Antiinflammatory Effects of Budesonide in Human Fetal Lung.
  18. Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns.
  19. Pharmacokinetics of Budesonide Administered with Surfactant in Premature Lambs: Implications for Neonatal Clinical Trials.
  20. Expression of human carcinoembryonic antigen-related cell adhesion molecule 6 and alveolar progenitor cells in normal and injured lungs of transgenic mice.
  21. Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide.
  22. Expression of Carcinoembryonic Cell Adhesion Molecule 6 and Alveolar Epithelial Cell Markers in Lungs of Human Infants with Chronic Lung Disease.
  23. Surface film formation in vitro by infant and therapeutic surfactants: role of surfactant protein B.
  24. Claudin-18 deficiency results in alveolar barrier dysfunction and impaired alveologenesis in mice.
  25. Inhaled nitric oxide increases urinary nitric oxide metabolites and cyclic guanosine monophosphate in premature infants: relationship to pulmonary outcome.
  26. Late administration of surfactant replacement therapy increases surfactant protein-B content: a randomized pilot study.
  27. Distribution and surfactant association of carcinoembryonic cell adhesion molecule 6 in human lung.
  28. A small-molecule smoothened agonist prevents glucocorticoid-induced neonatal cerebellar injury.
  29. Pilot trial of late booster doses of surfactant for ventilated premature infants.
  30. Re: 'The use of iNO in the newborn period: results from the European iNO registry'.
  31. HTII-280, a biomarker specific to the apical plasma membrane of human lung alveolar type II cells.
  32. Regulated gene expression in cultured type II cells of adult human lung.
  33. Two-year neurodevelopmental outcomes of ventilated preterm infants treated with inhaled nitric oxide.
  34. Economic evaluation of inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
  35. Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites.
  36. Carcinoembryonic cell adhesion molecule 6 in human lung: regulated expression of a multifunctional type II cell protein.
  37. Postnatal estradiol up-regulates lung nitric oxide synthases and improves lung function in bronchopulmonary dysplasia.
  38. Expression of nitric oxide synthases and endogenous NO metabolism in bronchopulmonary dysplasia.
  39. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to prevent) Chronic Lung Disease trial.
  40. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants.
  41. Surfactant function and composition in premature infants treated with inhaled nitric oxide.
  42. Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide.
  43. Developmental regulation of DUOX1 expression and function in human fetal lung epithelial cells.
  44. Role of endogenous TGF-beta in glucocorticoid-induced lung type II cell differentiation.
  45. Thyroid transcription factor in differentiating type II cells: regulation, isoforms, and target genes.
  46. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation.
  47. Lipidomics of cellular and secreted phospholipids from differentiated human fetal type II alveolar epithelial cells.
  48. Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulmonary gene expression.
  49. Gene induction during differentiation of human pulmonary type II cells in vitro.
  50. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome.
  51. Surfactant composition and function in a primate model of infant chronic lung disease: effects of inhaled nitric oxide.
  52. Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung.
  53. Effects of transgene expression of superoxide dismutase and glutathione peroxidase on pulmonary epithelial cell growth in hyperoxia.
  54. Dysfunction of pulmonary surfactant in chronically ventilated premature infants.
  55. Developmental regulation of claudin localization by fetal alveolar epithelial cells.
  56. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease.
  57. Progressive lung disease and surfactant dysfunction with a deletion in surfactant protein C gene.
  58. Surfactant protein profile of pulmonary surfactant in premature infants.
  59. Plasma 3-nitrotyrosine and outcome in neonates with severe bronchopulmonary dysplasia after inhaled nitric oxide.
  60. Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea.
  61. Fetal lung maturation in estrogen-deprived baboons.
  62. Differentiation of human pulmonary type II cells in vitro by glucocorticoid plus cAMP.
  63. Transforming growth factor-beta inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors.
  64. Members of the C/EBP transcription factor family stimulate expression of the human and rat surfactant protein A (SP-A) genes.
  65. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3.
  66. Human surfactant protein B promoter in transgenic mice: temporal, spatial, and stimulus-responsive regulation.
  67. Multiple courses of antenatal corticosteroids are associated with early severe lung disease in preterm neonates.
  68. Recovery of rat type II cell surfactant components during primary cell culture.
  69. Maintenance of differentiated function of the surfactant system in human fetal lung type II epithelial cells cultured on plastic.
  70. Respiratory distress after intratracheal bleomycin: selective deficiency of surfactant proteins B and C.
  71. Association of plasma cortisol and chronic lung disease in preterm infants.
  72. Transforming growth factor-beta(1) regulation of surfactant protein B gene expression is mediated by protein kinase-dependent intracellular translocation of thyroid transcription factor-1 and hepatocyte nuclear factor 3.
  73. Scientific rationale for the use of antenatal glucocorticoids to promote fetal development.
  74. Pulmonary surfactant metabolism in infants lacking surfactant protein B.
  75. Developmental and glucocorticoid regulation of surfactant protein mRNAs in preterm lambs.
  76. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group.
  77. Hormonal regulation and cellular localization of fatty acid synthase in human fetal lung.
  78. Development of an assay for the extraction and quantification of nine 5-n-alkyl-5-ethyl barbituric acids in various rat tissues.
  79. Plasma thyroid hormones in premature infants: effect of gestational age and antenatal thyrotropin-releasing hormone treatment. TRH Collaborative Trial Participants.
  80. TGF-beta1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung.
  81. Surfactant protein B processing in human fetal lung.
  82. An approach to the evaluation and comparison of reversed-phase high-performance liquid chromatography stationary phases.
  83. Regulation of expression of human SP-A1 and SP-A2 genes in fetal lung explant culture.
  84. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia.
  85. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. North American Thyrotropin-Releasing Hormone Study Group.
  86. Targeting type II and Clara cells for adenovirus-mediated gene transfer using the surfactant protein B promoter.
  87. Glucocorticoid regulation of surfactant components in immature lambs.
  88. Expression and glucocorticoid regulation of surfactant protein C in human fetal lung.
  89. Phorbol ester down-regulation of lung surfactant protein B gene expression by cytoplasmic trapping of thyroid transcription factor-1 and hepatocyte nuclear factor 3.
  90. Transcriptional regulation of surfactant proteins SP-A and SP-B by phorbol ester.
  91. Enhanced distribution of adenovirus-mediated gene transfer to lung parenchyma by perfluorochemical liquid.
  92. Combined effects of fetal beta agonist stimulation and glucocorticoids on lung function of preterm lambs.
  93. Regulation of surfactant protein D in human fetal lung.
  94. Antenatal hormone therapy for improving the outcome of the preterm infant.
  95. Transcriptional regulation of human pulmonary surfactant proteins SP-B and SP-C by glucocorticoids.
  96. Neonatal respiratory disease due to surfactant protein B deficiency.
  97. The development and performance of a radioimmunoassay for the analysis of ZM 213,689, the major metabolite of meropenem--a carbapenem antibiotic--in plasma and urine.
  98. Partial deficiency of surfactant protein B in an infant with chronic lung disease.
  99. Surfactant protein B in human fetal lung: developmental and glucocorticoid regulation.
  100. Elemental composition of lamellar bodies from fetal and adult human lung.
  101. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids.
  102. Thyrotropin-releasing hormone for prevention of neonatal respiratory disease.
  103. Adenovirus-mediated gene transfer to human fetal lung ex vivo.
  104. Characterization of the promoter of human pulmonary surfactant protein B gene.
  105. Glucocorticoid and cAMP increase fatty acid synthetase mRNA in human fetal lung explants.
  106. The use of competitive displacement agents to resolve albumin binding problems observed during the development of a radioimmunoassay for ICI 215001.
  107. Hormonal regulation of cholinephosphate cytidylyltransferase in human fetal lung.
  108. Secretion of surfactant protein A and phosphatidylcholine from type II cells of human fetal lung.
  109. Biphasic glucocorticoid regulation of pulmonary SP-A: characterization of inhibitory process.
  110. Differential glucocorticoid regulation of the pulmonary hydrophobic surfactant proteins SP-B and SP-C.
  111. Plasma thyroid hormones and prolactin in premature infants and their mothers after prenatal treatment with thyrotropin-releasing hormone.
  112. Cyclic adenosine 3',5'-monophosphate increases beta-adrenergic receptor concentration in cultured human fetal lung explants and type II cells.
  113. Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid. TRH Study Group.
  114. Differentiation of type II cells during explant culture of human fetal lung is accelerated by endogenous prostanoids and adenosine 3',5'-monophosphate.
  115. Glucocorticoids and gene expression.
  116. Hormonally regulated proteins in cultured human fetal lung: analysis by two-dimensional gel electrophoresis.
  117. Beta-adrenergic receptors and cAMP response increase during explant culture of human fetal lung: partial inhibition by dexamethasone.
  118. Lamellar bodies of cultured human fetal lung: content of surfactant protein A (SP-A), surface film formation and structural transformation in vitro.
  119. Interferon-gamma and synthesis of surfactant components by cultured human fetal lung.
  120. Glucocorticoid stimulation of fatty acid synthesis in explants of human fetal lung.
  121. Chromatographic retention relationships between aliphatic tertiary amines and their putative N-oxide metabolites--preliminary results.
  122. Hormonal control of lung maturation.
  123. Meclofenamate does not affect lung development in fetal sheep.
  124. Hormonal regulation of pulmonary surfactant.
  125. Regulation of messenger RNAs for the hydrophobic surfactant proteins in human lung.
  126. Glucocorticoids both stimulate and inhibit production of pulmonary surfactant protein A in fetal human lung.
  127. Synthesis of surfactant components by cultured type II cells from human lung.
  128. Low molecular weight human pulmonary surfactant protein (SP5): isolation, characterization, and cDNA and amino acid sequences.
  129. Surfactant protein of molecular weight 28,000-36,000 in cultured human fetal lung: cellular localization and effect of dexamethasone.
  130. Beta-adrenergic receptors and cyclic adenosine monophosphate generation in human fetal lung.
  131. Glucocorticoid regulation of lung maturation.
  132. Regulation of pulmonary surfactant apoprotein SP 28-36 gene in fetal human lung.
  133. Isolation and characterization of differentiated alveolar type II cells from fetal human lung.
  134. Lung beta-adrenoreceptor blockade affects perinatal surfactant release but not lung water.
  135. Endogenous corticoids and lung development in the fetal rabbit.
  136. Glucocorticoids and thyroid hormones stimulate biochemical and morphological differentiation of human fetal lung in organ culture.
  137. Hormones and lung maturation.
  138. Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs.
  139. Combined hormonal treatment and lung maturation.
  140. Thyroid hormone stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung.
  141. Corticosteroid binding by fetal rat and rabbit lung in organ culture.
  142. Thyroid hormones and plasma corticosteroid binding globulin capacity in fetal and newborn lambs.
  143. Corticosteroid stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung: evidence for de novo protein synthesis mediated by glucocorticoid receptors.
  144. Hormones and receptors in developing lung.
  145. Mode of action of glucocorticoids on lung maturation.
  146. Glucocorticoid activity in cord serum: comparison of hydrocortisone and betamethasone regimens.
  147. Nuclear 3,5,3'-triiodothyronine receptors in rabbit lung: characterization and developmental changes.
  148. Ontogeny and regulation of corticosteroid binding globulin capacity in plasma of fetal and newborn lambs.
  149. Inhibitors of prostaglandin synthesis, tracheal fluid, and surfactant in fetal lambs.
  150. Effects of antenatal glucocorticoid administration on ductus arteriosus of preterm lambs.
  151. Identification and characterization of nuclear 3,5,3'-triiodothyronine-binding sites in fetal human lung.
  152. Prenatal administration of betamethasone for prevention of patient ductus arteriosus.
  153. Glucocorticoids increase pulmonary beta-adrenergic receptors in fetal rabbit.
  154. Fetal sex and prenatal betamethasone therapy.
  155. Glucocorticoids in prevention of respiratory distress syndrome.
  156. Transplacental stimulation of lung development in the fetal rabbit by 3,5-dimethyl-3'-isopropyl-L-thyronine.
  157. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome.
  158. Hormonal influences during fetal lung development.
  159. Tracheal fluid in fetal lambs: spontaneous decrease prior to birth.
  160. Prolactin in umbilical cord blood and the respiratory distress syndrome.
  161. Corticosteroids and respiratory distress syndrome: status 1979.
  162. Delivery and transport of glucocorticoids to target cells.
  163. Glucocorticoids and differentiation.
  164. Prenatal administration of betamethasone for prevention of respiratory distress syndrome.
  165. Prolactin in umbilical cord blood and the respiratory distress syndrome.
  166. Triiodothyronine nuclear binding in fetal and adult rabbit lung and cultured lung cells.
  167. Failure to detect an effect of prolactin on pulmonary surfactant and adrenal steroids in fetal sheep and rabbits.
  168. Glucocorticoid binding by isolated lung cells.
  169. Hormonal regulation of surfactant in fetal life.
  170. Glucocorticoid receptors in the lung.
  171. Betamethasone and cortisol in prevention of respiratory distress syndrome.
  172. Corticosteroid induction of phosphatidic acid phosphatase in fetal rabbit lung.
  173. Glucocorticoid effects in the fetal lung.
  174. Radioimmunoassay of pulmonary surface-active material in the tracheal fluid of the fetal lamb.
  175. The role of sulfhydryl groups in the binding of glucocorticoids by cytoplasmic receptors of lung and other mammalian tissues.
  176. Use of prenatal glucocorticoid therapy to prevent respiratory distress syndrome. A supporting view.
  177. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome.
  178. Ontogeny of tracheal fluid, pulmonary surfactant, and plasma corticoids in the fetal lamb.
  179. A radioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man.
  180. A study of the cytoplasmic receptors for glucocorticoids in intestine of pre- and postweanling rats.
  181. General presence of glucocorticoid receptors in mammalian tissues.
  182. Cytoplasmic receptor for glucocorticoids in lung of the human fetus and neonate.
  183. Glucocorticoid receptors and the role of glucocorticoids in fetal lung development.
  184. Glucocorticoid-induced alteration of the surface membrane of cultured hepatoma cells.
  185. Hormone induced modification of the cell surface.